Search Results
Search for other papers by A Coopes in
Google Scholar
PubMed
Search for other papers by C E Henry in
Google Scholar
PubMed
Search for other papers by E Llamosas in
Google Scholar
PubMed
Search for other papers by C E Ford in
Google Scholar
PubMed
, De Craene & Berx 2013 , Kanzawa et al . 2013 ). While β-catenin dependent signalling has a documented role in endometrial cancer, little is known about non-canonical (also known as β-catenin independent) signalling and its potential therapeutic
Search for other papers by G Capurso in
Google Scholar
PubMed
Search for other papers by S Lattimore in
Google Scholar
PubMed
Search for other papers by T Crnogorac-Jurcevic in
Google Scholar
PubMed
Search for other papers by F Panzuto in
Google Scholar
PubMed
Search for other papers by M Milione in
Google Scholar
PubMed
Search for other papers by V Bhakta in
Google Scholar
PubMed
Search for other papers by N Campanini in
Google Scholar
PubMed
Search for other papers by S M Swift in
Google Scholar
PubMed
Search for other papers by C Bordi in
Google Scholar
PubMed
Search for other papers by G Delle Fave in
Google Scholar
PubMed
Search for other papers by N R Lemoine in
Google Scholar
PubMed
receptors and intracellular signalling to oxidative stress and stromal reaction. As one of our aims was to provide potential novel biomarkers, we focused on genes previously not associated with PETs, which may be useful diagnostic or therapeutic
Department of Surgery, Division of Endocrinology and Metabolism, Mackay Junior College of Medicine, Department of Pharmacology, Department of Medical Research, Institute of Statistical Science
Department of Surgery, Division of Endocrinology and Metabolism, Mackay Junior College of Medicine, Department of Pharmacology, Department of Medical Research, Institute of Statistical Science
Search for other papers by Shih-Ping Cheng in
Google Scholar
PubMed
Department of Surgery, Division of Endocrinology and Metabolism, Mackay Junior College of Medicine, Department of Pharmacology, Department of Medical Research, Institute of Statistical Science
Search for other papers by Chien-Liang Liu in
Google Scholar
PubMed
Department of Surgery, Division of Endocrinology and Metabolism, Mackay Junior College of Medicine, Department of Pharmacology, Department of Medical Research, Institute of Statistical Science
Department of Surgery, Division of Endocrinology and Metabolism, Mackay Junior College of Medicine, Department of Pharmacology, Department of Medical Research, Institute of Statistical Science
Search for other papers by Ming-Jen Chen in
Google Scholar
PubMed
Department of Surgery, Division of Endocrinology and Metabolism, Mackay Junior College of Medicine, Department of Pharmacology, Department of Medical Research, Institute of Statistical Science
Search for other papers by Ming-Nan Chien in
Google Scholar
PubMed
Department of Surgery, Division of Endocrinology and Metabolism, Mackay Junior College of Medicine, Department of Pharmacology, Department of Medical Research, Institute of Statistical Science
Search for other papers by Ching-Hsiang Leung in
Google Scholar
PubMed
Search for other papers by Chi-Hsin Lin in
Google Scholar
PubMed
Search for other papers by Yi-Chiung Hsu in
Google Scholar
PubMed
Department of Surgery, Division of Endocrinology and Metabolism, Mackay Junior College of Medicine, Department of Pharmacology, Department of Medical Research, Institute of Statistical Science
Department of Surgery, Division of Endocrinology and Metabolism, Mackay Junior College of Medicine, Department of Pharmacology, Department of Medical Research, Institute of Statistical Science
Search for other papers by Jie-Jen Lee in
Google Scholar
PubMed
concurrent lymphocytic thyroiditis. Given that CD74 is overexpressed in thyroid cancer and associated with advanced tumor stage, we hypothesize that CD74 might be a potential therapeutic target in thyroid cancer. Table 1 Correlation of macrophage migration
Search for other papers by K W Colston in
Google Scholar
PubMed
Search for other papers by L Jerome in
Google Scholar
PubMed
Search for other papers by L Shiry in
Google Scholar
PubMed
Search for other papers by B Leyland-Jones in
Google Scholar
PubMed
The IGF system performs a fundamental role in the regulation of cellular proliferation, differentiation and apoptosis. These diverse biological actions are mediated primarily by IGF association with the type I IGF receptor (IGF-IR), which is in turn regulated by a group of high-affinity IGF-binding proteins (IGFBP-1 to -6). All of the IGFBPs can have growth-inhibitory effects by competitively binding IGFs and preventing their association with the IGF-IR. IGFBP-3 is the most abundant binding protein in the circulation and controls the actions of the IGFs by regulating their distribution and bioavailability to target tissues. Disruptions in the balance of IGF system components leading to excessive proliferation and survival signals have been implicated in the development of different tumor types. Epidemiological evidence indicates that increased levels of IGF-I, reduced levels of IGFBP-3 or an increased ratio of IGF-I to IGFBP-3 in the circulation are associated with an increased risk for the development of several common cancers, including those of the breast, prostate, lung and colon. The results of preclinical studies indicate that a diversity of interventions which antagonize IGF-IR signaling or augment IGFBP-3 function inhibit tumor cell growth in models of human cancers. A more comprehensive understanding of the interplay between cellular targets of the IGF system and antineoplastic agents will facilitate the development of novel strategies for the prevention and treatment of cancer.
Search for other papers by R L Sutherland in
Google Scholar
PubMed
Search for other papers by O W J Prall in
Google Scholar
PubMed
Search for other papers by K M Alle in
Google Scholar
PubMed
Search for other papers by N R C Wilcken in
Google Scholar
PubMed
Search for other papers by R Hui in
Google Scholar
PubMed
Search for other papers by J R Ball in
Google Scholar
PubMed
Search for other papers by B Sarcevic in
Google Scholar
PubMed
Search for other papers by S M Henshall in
Google Scholar
PubMed
Search for other papers by E A Musgrove in
Google Scholar
PubMed
Search for other papers by C K W Watts in
Google Scholar
PubMed
Search for other papers by Omar Abdel-Rahman in
Google Scholar
PubMed
Search for other papers by Angela Lamarca in
Google Scholar
PubMed
Clinical Oncology Department, Department of Medical Oncology, University of Manchester, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Search for other papers by Juan W Valle in
Google Scholar
PubMed
Search for other papers by Richard A Hubner in
Google Scholar
PubMed
in HCC (including sorafenib), and a number of molecular targets have been identified paving new avenues for potential therapeutic opportunities. Such molecular targets include MAP kinase pathway alterations ( Galuppo et al . 2014 ), vascular
Cancer Genetics, Department of Endocrinology, Kolling Institute of Medical Research
Search for other papers by Justin S Gundara in
Google Scholar
PubMed
Search for other papers by JingTing Zhao in
Google Scholar
PubMed
Cancer Genetics, Department of Endocrinology, Kolling Institute of Medical Research
Search for other papers by Bruce G Robinson in
Google Scholar
PubMed
Cancer Genetics, Department of Endocrinology, Kolling Institute of Medical Research
Search for other papers by Stan B Sidhu in
Google Scholar
PubMed
important to cell death as it is to survival. Now that we are gaining a more thorough understanding of the mechanisms underlying autophagy, its relevance to human disease and burgeoning therapeutic potential are being unravelled ( Ding et al . 2008 , Chen
Search for other papers by Hira Lal Goel in
Google Scholar
PubMed
Search for other papers by Jing Li in
Google Scholar
PubMed
Search for other papers by Sophia Kogan in
Google Scholar
PubMed
Search for other papers by Lucia R Languino in
Google Scholar
PubMed
metastatize to the bone and point to α v β 3 as a potential therapeutic target to block prostate cancer osteoblastic lesions ( Keller & Brown 2004 , McCabe et al . 2007 ). Besides therapeutic applications, other uses of integrin inhibitors are in the area
Search for other papers by Woo Kyung Lee in
Google Scholar
PubMed
Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Search for other papers by Won Gu Kim in
Google Scholar
PubMed
Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
Search for other papers by Laura Fozzatti in
Google Scholar
PubMed
Search for other papers by Sunmi Park in
Google Scholar
PubMed
Search for other papers by Li Zhao in
Google Scholar
PubMed
Search for other papers by Mark C Willingham in
Google Scholar
PubMed
Search for other papers by David Lonard in
Google Scholar
PubMed
Search for other papers by Bert W O’Malley in
Google Scholar
PubMed
Search for other papers by Sheue-yann Cheng in
Google Scholar
PubMed
-3 is a tumor promoter in thyroid cancer and, importantly, that SRC-3 could be a potential therapeutic target of thyroid cancer. Many small molecule inhibitors (SMIs) have been identified and developed for targeting mainly the enzyme substrate
